Obigen Pharma

Obigen Pharma Equity

The The Equity of Obigen Pharma (7876.TWO) as of Oct 18, 2026 is 1.68 B TWD. In the previous year, The Equity was 1.93 B TWD — a change of -13.30% (lower).

Equity

1.68 BTWD

YoY

-13.30%

Last updated:

In 2024, Obigen Pharma's equity was 1.68 B TWD, a -13.30% increase from the 1.93 B TWD equity in the previous year.

The Obigen Pharma Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
1.48 B TWD
Jan 1, 2023
1.93 B TWD
Jan 1, 2024
1.68 B TWD
The Obigen Pharma Equity history
YEAREquityYoY
1.68 BTWD-13.30%
1.93 BTWD+30.12%
1.48 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Obigen Pharma Stock analysis

What does Obigen Pharma do? Obigen Pharma Inc, listed on the Taiwan Stock Exchange under ticker 7876.TWO with ISIN TW0007876005, is a biotechnology company headquartered in Zhubei, Taiwan. The company operates within the Health Care sector and currently employs 57 full-time staff. Obigen Pharma is engaged in the research, development, manufacturing, and commercialization of novel botulinum toxin products. Its primary product, OBI-858, is a type A botulinum toxin formulation currently in phase II clinical trials in Taiwan for the treatment of frown lines in medical aesthetics. The company has established a complete supply chain for OBI-858 within Taiwan, covering research, development, and production. It collaborates with contract research organizations (CROs) to support the advancement of clinical trials for its drug candidates. The company's initial public offering (IPO) is scheduled for November 24, 2025. Obigen Pharma maintains a corporate website at www.obigenpharma.com for further information. Obigen Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Obigen Pharma's Equity

Obigen Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Obigen Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Obigen Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Obigen Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Obigen Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Obigen Pharma stock

The Equity of Obigen Pharma is 1.68 B TWD in 2024.

The Equity of Obigen Pharma changed from 1.93 B TWD to 1.68 B TWD, representing a -13.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Obigen Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Obigen Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Obigen Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Obigen Pharma